A study of 2.7 million cancer patients asked one plain question. How long do you wait between the diagnosis and the first treatment? The answer depended less on the tumor than on the insurance card.
That is an uncomfortable sentence. The data behind it is not close.
What 2.7 million records show
The study ran in JAMA Surgery. It covered patients diagnosed with non-metastatic breast, colon, lung, pancreatic, gastric and esophageal cancers between January 2012 and December 2023.
Median waits from diagnosis to the first course of treatment rose over that period for every cancer studied. The increases ranged from nine to 14 days.
Then the sorting starts. Patients with private insurance waited the least. Patients on Medicaid waited the longest, longer even than patients with no coverage at all.
Across five of those cancers, Medicaid patients were 11% to 42% more likely than privately insured patients to wait more than a month. Medicare patients fared better but were still 4% to 12% more likely to cross that line.
Waiting is not free. The researchers noted that delayed surgical care is linked to roughly 20% to 30% higher 90-day and five-year mortality in lung cancer, and 10% to 15% higher mortality in breast cancer.
| What the study found | Reading |
|---|---|
| Cancer patients studied, 2012 to 2023 | 2.7 million |
| Median wait, diagnosis to first treatment | 9 to 14 days |
| Medicaid vs. private, odds of waiting past a month | +11% to +42% |
| Medicare vs. private, odds of waiting past a month | +4% to +12% |
| Hospital margin on Medicare dollars, 2024 | −12% |
| Private payment vs. Medicare rates | 2.5x |
Why the line forms
The researchers point at capacity. Cancer hospitals may not have enough operating rooms and specialists for everyone referred to them.
The Journal's August 28 editorial adds a second cause. Low physician payment rates make it hard for Medicaid patients to get a specialist appointment in the first place.
The uninsured do relatively well for an odd reason. Tax-exempt hospitals, which include many large cancer centers, are required to run charity-care programs. Carrying no card can beat carrying one nobody wants.
The pattern repeats elsewhere. A separate JAMA study found Medicaid and Medicare patients face longer emergency-room waits before admission, and hospitals serving more Medicaid patients had longer waits overall.
The arithmetic underneath is blunt. Congress's Medicare Payment Advisory Commission estimates hospitals lost about 12 cents on every Medicare dollar in 2024.
Meanwhile a 2024 Rand study found private insurers paid hospitals more than 2.5 times Medicare rates. Public underpayment plus private overpayment is what keeps the lights on.
It is not elegant. It is load-bearing. Equalize the rates and hospitals freeze hiring first, then cut staff and close money-losing services like obstetrics and behavioral health.
The same fight, in pill form
Coverage decides access to medicines too, and the GLP-1 weight-loss drugs are the current test case.
A Mercer survey of 481 large organizations found 6% dropped GLP-1 coverage in 2026 and another 5% planned to drop it in 2027. Another 27% tightened the rules, and 45% never covered the drugs at all.
One hospital operator with more than 300,000 workers stopped covering them for weight loss after use on its employee plan surged 90% in 2025. It still covers them for diabetes.
A large Massachusetts insurer said unchecked GLP-1 costs would have approached $1 billion, about seven times the $140 million it spent in 2023.
Patients pay anywhere from a $149 cash price to a $1,350 monthly list price. Where you land depends on your plan, not on your body.
Medicare's temporary pathway lets eligible seniors get the drugs for a $50 monthly copay. KFF estimated 3.8 million people qualify, out of more than 13 million older Americans who are overweight or obese.
None of this is cause for panic. It is cause to know exactly which card you will be carrying at 66, and to fund the answer before you need it.